ReviewTherapeutic advances in musculoskeletal disease2015
B-cell survival factors in autoimmune rheumatic disorders.
Review in Therapeutic advances in musculoskeletal disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.International journal of molecular sciences · 2024Article
- Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.Life (Basel, Switzerland) · 2023Review
- BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis.Acta pharmacologica Sinica · 2021Article
- Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder.Frontiers in neurology · 2021Article
- B Cells in Rheumatoid Arthritis：Pathogenic Mechanisms and Treatment Prospects.Frontiers in immunology · 2021Review
- Applications and potential mechanisms of herbal medicines for rheumatoid arthritis treatment: a systematic review.RSC advances · 2019Review
- Paeoniflorin-6'-O-benzene sulfonate alleviates collagen-induced arthritis in mice by downregulating BAFF-TRAF2-NF-κB signaling: comparison with biological agents.Acta pharmacologica Sinica · 2019Article
- Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis.Clinical rheumatology · 2018Article
- Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults.Clinical rheumatology · 2018Article
- Recent advances in the management of systemic lupus erythematosus.F1000Research · 2018Review
- Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.Brain and behavior · 2017Article
- Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2017Review
- Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Clinical pharmacokinetics · 2017Review
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.Drug design, development and therapy · 2017Review
- B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Digestive diseases and sciences · 2016Review
- VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry.Molecular immunology · 2016Article
- Unintended Immunological Consequences of Biologic Therapy.Current allergy and asthma reports · 2016Review
- Deciphering the Potential Pharmaceutical Mechanism of Chinese Traditional Medicine (Gui-Zhi-Shao-Yao-Zhi-Mu) on Rheumatoid Arthritis.Scientific reports · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune rheumatic disorders have complex etiopathogenetic mechanisms in which B cells play a central role. The importance of factors stimulating B cells, notably the B-cell activating factor (BAFF) and A proliferation inducing ligand (APRIL) axis is now recognized. BAFF and APRIL are cytokines essential for B-cell proliferation and survival from the immature stages to the development of plasma cells. Their levels are increased in some subsets of patients with autoimmune disorders. Several recent biologic drugs have been developed to block this axis, namely belimumab [already licensed for systemic lupus erythematosus (SLE) treatment], tabalumab, atacicept and blisibimod. Many clinical trials to evaluate the safety and efficacy of these drugs in several autoimmune disorders are ongoing, or have been completed recently. This review updates the information on the use of biologic agents blocking BAFF/APRIL for patients with SLE, rheumatoid arthritis, Sjögren's syndrome and myositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.